Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdampartner
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result

LabGenius: London-based startup gets €11.5M for discovering next-gen drugs using AI

Akansha Srivastava by Akansha Srivastava
October 23, 2019
in News, (Crowd)funding, AI and chatbots, Startups
0
LabGenius: London-based startup gets €11.5M for discovering next-gen drugs using AI
44
SHARES
LinkedInTwitterWhatsAppFacebook

The growth in Artificial Intelligence (AI) has proliferated into various sectors. A lot of startups across the world are creating new approaches and seeking after the inventive business models in a bid to alter the pharmaceutical businesses.

London-based drug discovery company, LabGenius has announced today that it has raised over $10 million (€11.5 million) in its Series A financing round. LabGenius is a drug discovery company that is using artificial intelligence (AI), robotic automation, and synthetic biology to discover novel protein therapeutics.

 - Partner content -
Cost of software - The Software house
The cost of building software
Marek Gajda, CTO of The Software House, shares his insights on building high-quality...Show More
Marek Gajda, CTO of The Software House, shares his insights on building high-quality software. Show Less
Read more

The company has developed EVA – a robot scientist capable of designing, conducting, and learning from its own experiments. Importantly, the learning aspect means that EVA gets continuously smarter as it unpicks the genetic design rules that underpin life.

The Series A investment round was led by Lux Capital and Obvious Ventures, with participation from Felicis Ventures, Inovia Capital, Gigafund, Air Street Capital and existing investors. The round also included participation from Recursion Pharmaceuticals’ Founder & CEO Chris Gibson as well as Inovia Capital General Partner Patrick Pichette who was formerly Google’s CFO. Zavain Dar, Partner at Lux Capital and Nan Li, Managing Director at Obvious Ventures, will join the company’s board of directors.

LabGenius will use the capital to scale its team, expand the scope of its discovery platform, and initiate an internal asset development program. Through this internal asset development program, the company will evolve novel antibody fragments capable of treating conditions that cannot be addressed using conventional antibody formats.

LabGenius Founder and CEO, Dr. James Field, says

Protein therapeutics have an unparalleled potential to both treat disease and alleviate human suffering. By transforming how these drugs are discovered, we have a shot at improving the lives of countless people. Being able to robustly engineer novel therapeutic proteins has immense commercial and societal value. The discovery of protein therapeutics has historically been highly artisanal, relying heavily on humans for both experimental design and execution. This dependence has proved limiting because, as a species, we’re cognitively incapable of fully grasping the complexity of biological systems.

Zavain Dar, Partner at Lux Capital, said:

We’ve seen this playbook before. Bringing to bear multiple technologies to remove human bias from the pursuit of human health. We’re thrilled to co-lead the Series A with Obvious Ventures and back a truly bold vision with the potential for massive impact.

Nan Li, Managing Director at Obvious Ventures, said:

We have high conviction that computational approaches to protein engineering hold tremendous promise. After researching the space and meeting many companies, we believe that LabGenius is the clear breakout leader. We are beyond excited to co-lead the Series A and help the company realize their very ambitious vision to discover new protein therapies using AI.

— Press release

Stay tuned to Silicon Canals for more European technology news.

Meet‌ ‌Sponsh,‌ ‌the‌ ‌Dutch‌ ‌startup‌ ‌that‌ ‌is‌ ‌extracting‌ ‌water‌ ‌from‌ ‌air‌ ‌to‌ ‌fight‌ ‌water shortage‌ ‌

close

Want to stay on top of the latest rounds, coolest tech and hottest startups?

Subscribe to our free, daily news blast and stay up-to-date!

Check your inbox or spam folder to confirm your subscription.

 - Partner content -
Nebula CTO Andre Witte
Cloud spend management 😱
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the...Show More
Tracking cloud spend can be tricky. Learn from Nebula's CTO Andre Witte how to keep the costs at bay in 2021. Show Less
Read more
Tags: AIfundinglondonstartups
Share2Tweet8SendShare25

Featured events

07apr10:0012:30FeaturedWorkshop: pr for startupsHow to grow your startup with the help of public relations

Partner content | Work with us

Blue Tulip Awards celebrates International Women’s Day: maximum performance can only come from a diverse team

Future Hamburg Award: Looking for the best startups to forge the city of the future

The Humblebrag launches online course to help emerging leaders amplify their visibility and voice

Blue Tulip Awards announce 5 finalists in the Food & Water and Education & Employment theme

Impact media foundation 5 Media offers grants up to €100,000 per year to drive a sustainable future

Breaking news from Amsterdam | Partner

Amsterdam’s Crisp raises €30M: Here’s what this online-only supermarket plans to do with this capital

Amsterdam-based Tellow’s parent company raises €60.2M: An interview with Thomas Vles, Tellow’s new CEO

Amsterdam-based fast-charging startup Fastned charges itself with €150M through accelerated bookbuild offering

Amsterdam-based Founda Health raises €12.3M to build infrastructure for global healthcare sector; here’s how

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy policy
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2020 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • COVID-19
    • Startups
    • Scaleups
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
  • Features
    • Promoted content
    • How-to
    • Knowledge & Insights
    • Guest Contributions
    • Scaling-up in Europe
  • Amsterdam
  • Events
  • Newsletter
  • Jobs
  • About
    • Partner with Silicon Canals
    • Team
    • Contact

Silicon Canals 2014-2020 | Website: Bright Idiots

X

This website uses cookies to ensure the best possible experience. We may share this information with our advertising and analytics partners. By clicking 'Accept', you agree to our use of cookies and similar technologies. More info